Jones, J. R. http://orcid.org/0000-0002-1401-6105
Barber, A.
Le Bihan, Y-V http://orcid.org/0000-0002-6850-9706
Weinhold, N.
Ashby, C. http://orcid.org/0000-0002-9361-0283
Walker, B. A. http://orcid.org/0000-0002-8615-6254
Wardell, C. P. http://orcid.org/0000-0002-9416-7818
Wang, H.
Kaiser, M. F.
Jackson, G. H.
Davies, F. E.
Chopra, R.
Morgan, G. J. http://orcid.org/0000-0002-4271-6360
Pawlyn, C. http://orcid.org/0000-0002-7190-0028
Article History
Received: 20 May 2021
Revised: 26 July 2021
Accepted: 27 July 2021
First Online: 9 August 2021
Competing interests
: JRJ: Celgene Corporation-honoraria, research funding. MFK: Chugai-consultancy; Bristol-Myers Squibb, Takeda–consultancy, travel support; Janssen, Amgen–consultancy, honoraria; Celgene Corporation–consultancy, honoraria, research funding. GHJ: Roche, Amgen, Janssen, Merck Sharp, and Dohme–consultancy, honoraria, speakers bureau; Celgene Corporation, Takeda–consultancy, honoraria, travel support, research funding, speakers bureau. FED: Adaptive–honoraria; Celgene Corporation–consultancy, honoraria, research funding; Janssen, Oncopeptide, Roche, Sanofi, Takeda–consultancy, honoraria. RC: Celgene Corporation–previous employment, Monte Rosa Therapeutics - founder. GJM: Janssen–research funding; Bristol-Myers Squibb, Takeda, Roche, Amgen, GSK, Karyopharm–consultancy, honoraria; Celgene Corporation–consultancy, honoraria, research funding. CP: Amgen, Takeda–consultancy, travel support; Janssen–honoraria, travel support; Celgene Corporation–consultancy, honoraria, travel support; Sanofi–consultancy, honoraria. The ICR has a financial interest in the development of compounds targeting CRL4-CRBN E3-ubiquitin ligase. YVLB, HW, RC, CP are involved in collaborative projects with Monte Rosa Therapeutics. All other authors declare no competing interests.